康辰药业大幅上涨 ZY5301临床研究结果获国际认可

智选洞察07-31

07月31日，康辰药业（603590）股价大幅上涨，截至13点01分，康辰药业上涨5.05%，报23.73元/股，成交2224万元，换手率0.61%，振幅5.62%。消息解读康辰药业公告，ZY5301是公司拥有自主知识产权的中药创新药，聚焦于治疗女性盆腔炎性疾病后遗症慢性盆腔痛的临床研究。近期，ZY5301 Ⅱ期临床研究结果(CTR20202153)在经多位国际评审专家严苛审评后，《JAMA ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2455924863?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-31 13:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2455924863","market":"sh","top_or_hot":-1,"title":"康辰药业大幅上涨 ZY5301临床研究结果获国际认可","media":"智选洞察","content":"<div>\n<p>07月31日，康辰药业（603590）股价大幅上涨，截至13点01分，康辰药业上涨5.05%，报23.73元/股，成交2224万元，换手率0.61%，振幅5.62%。消息解读康辰药业公告，ZY5301是公司拥有自主知识产权的中药创新药，聚焦于治疗女性盆腔炎性疾病后遗症慢性盆腔痛的临床研究。近期，ZY5301 Ⅱ期临床研究结果(CTR20202153)在经多位国际评审专家严苛审评后，《JAMA ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240731130802af95043a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康辰药业大幅上涨 ZY5301临床研究结果获国际认可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康辰药业大幅上涨 ZY5301临床研究结果获国际认可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-31 13:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240731130802af95043a&s=b><strong>智选洞察</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>07月31日，康辰药业（603590）股价大幅上涨，截至13点01分，康辰药业上涨5.05%，报23.73元/股，成交2224万元，换手率0.61%，振幅5.62%。消息解读康辰药业公告，ZY5301是公司拥有自主知识产权的中药创新药，聚焦于治疗女性盆腔炎性疾病后遗症慢性盆腔痛的临床研究。近期，ZY5301 Ⅱ期临床研究结果(CTR20202153)在经多位国际评审专家严苛审评后，《JAMA ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240731130802af95043a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603590","symbol_name":"康辰药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240731130802af95043a&s=b","article_id":"2455924863","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240731130802af95043a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2455924863","pubTimestamp":1722402119,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"消息解读康辰药业公告，ZY5301是公司拥有自主知识产权的中药创新药，聚焦于治疗女性盆腔炎性疾病后遗症慢性盆腔痛的临床研究。近期，ZY5301 Ⅱ期临床研究结果在经多位国际评审专家严苛审评后，《JAMA Network Open》正式接受并刊出。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603590":"康辰药业","BK0239":"医药制造"},"translate_title":"Kangchen Pharmaceutical rose sharply, ZY5301 clinical research results were internationally recognized","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603590":1},"content_text":"07月31日，康辰药业（603590）股价大幅上涨，截至13点01分，康辰药业上涨5.05%，报23.73元/股，成交2224万元，换手率0.61%，振幅5.62%。消息解读康辰药业公告，ZY5301是公司拥有自主知识产权的中药创新药，聚焦于治疗女性盆腔炎性疾病后遗症慢性盆腔痛的临床研究。近期，ZY5301 Ⅱ期临床研究结果(CTR20202153)在经多位国际评审专家严苛审评后，《JAMA Network Open》正式接受并刊出。据悉，《美国医学会杂志(JAMA)》是国际权威顶尖医学期刊，《JAMA Network Open》为其子刊，2022年影响因子13.8，ZY5301 Ⅱ期临床研究结果在其刊出，不仅体现了国际期刊对ZY5301 Ⅱ期临床研究的科学性、严谨性的高度认可，还体现了其对治疗女性盆腔炎性疾病后遗症慢性盆腔痛的有效性与安全性的高度认可。这是《JAMA》系列期刊首次刊登中国中药在该治疗领域的临床研究结果。7月30日，国家药监局党组书记、局长李利主持召开会议，研究部署创新药临床试验审评审批改革工作，审议通过《优化创新药临床试验审评审批试点工作方案》。会议指出，药物临床试验是创新药研发的关键环节，开展优化创新药临床试验审评审批试点工作，是持续深化审评审批制度改革，提升临床试验质量和效率，促进医药新质生产力发展的重要举措。此次试点工作针对创新药临床试验限速的关键环节，探索建立提升药物临床试验质量和效率的工作制度和机制，实现30个工作日内完成创新药临床试验申请的审评审批，推动试点区域缩短药物临床试验启动用时的目标。试点工作将在临床试验配套管理和支持政策完善、创新药临床研发领域产业服务能力强的区域开展，创新药临床试验申请人申请纳入试点项目不受区域限制。试点方案对试点申请条件、工作实施步骤、时间安排、保障措施等进行了部署。《优化创新药临床试验审评审批试点工作方案》将于近日发布。此外，数据统计显示，近半年内1家券商给予增持建议，8家券商给予买入建议。资金动向截止发稿，康辰药业获得主力净流出14万元，其中超大单流入130万元，大单流出143万元。数据显示，该股今日净流入较近5日净流入均值减少62万元。北向资金方面，康辰药业07月30日获得北向资金增持5.00万股，截至07月30日，北向资金当前共持有康辰药业29.86万股，市值708万元，持股占流通股比为0.18%。主营业务及业绩康辰药业公司主营业务为以创新药研发为核心、以临床需求为导向，集研发、生产和销售于一体。最新财报显示，今年一季报，康辰药业实现营业收入1.99亿元，同比增长20.67%，净利润为4,165.43万元，同比增长62.28%，基本每股收益为0.27元。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2455924863"}